Trends in Abuse of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004


      OxyContin® (Purdue Pharma L.P., Stamford, Conn) was approved by the Food and Drug Administration (FDA) in 1995 as a sustained-release preparation of oxycodone hydrochloride and was thought to have much lower abuse potential than immediate-release oxycodone because of its slow-release properties. However, beginning in 2000, widespread reports of OxyContin® abuse surfaced. In response, Purdue Pharma L.P. sponsored the development of a proactive abuse surveillance program, named the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) system. In this paper, we describe results obtained from one aspect of RADARS—the use of drug abuse experts (ie, key informants)—as a source of data on the prevalence and magnitude of abuse of prescription drugs. The results indicate that prescription drug abuse has become prevalent, with cases reported in 60% of the zip codes surveyed. The prevalence of abuse was rank ordered as follows: OxyContin ≥ hydrocodone > other oxycodone > methadone > morphine > hydromorphone > fentanyl > buprenorphine. In terms of the magnitude of abuse (≥5 cases/100,000 persons in a 3-digit zip code), modest growth was seen with all analgesics over the 10 calendar quarters we monitored, but was most pronounced with OxyContin and hydrocodone. These results indicate that OxyContin abuse is a pervasive problem in this country, but that it needs to be considered in the context of a general pattern of increasing prescription drug abuse.


      Over the past 5 years, there have been reports, frequently anecdotal, that opioid analgesic abuse has evolved into a national epidemic. In this study, we report systematic data to indicate that opioid analgesic abuse has in fact increased among street and recreational drug users, with OxyContin and hydrocodone products the most frequently abused. Steps need to be taken to reduce prescription drug abuse, but very great care needs to be exercised in the nature of these actions so the legitimate and appropriate use of these drugs in the treatment of pain is not compromised as a result.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Agar M.H.
        The Professional Stranger. Academic Press, Orlando, FL1980
        • Brands B.
        • Blake J.
        • Sproule B.
        • Gourlay D.
        • Busto U.
        Prescription opioid abuse in patients presenting for methadone maintenance treatment.
        Drug Alcohol Depend. 2004; 73: 199-207
        • Breitbart W.
        • Rosenfeld B.D.
        • Passik S.D.
        The under-treatment of pain in ambulatory AIDS patients.
        Pain. 1996; 65: 239-249
        • Center for Substance Abuse Treatment, Methadone-Associated Mortality
        Report of a National Assessment, May 8-9, 2003. SAMHSA, Publication Number 04-3904. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD2004
        • Cicero T.J.
        • Adams E.H.
        • Geller A.
        • Inciardi J.A.
        • Muñoz A.
        • Schnoll S.H.
        • Senay E.C.
        • Woody G.E.
        A post-marketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States.
        Drug Alcohol Depend. 1999; 57: 7-22
      1. Cicero TJ, Inciardi JA, Adams E, Geller A, Senay EC, Woody GE, Muñoz A: Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf, May 12, 2005 (Epub ahead of print)

        • Cicero T.J.
        • Inciardi J.A.
        Diversion and abuse of methadone prescribed for pain management.
        JAMA. 2005; 293: 297-298
        • Cleeland C.S.
        • Gonin R.
        • Hatfield A.
        Pain and its treatment in outpatient with metastatic cancer.
        N Engl J Med. 1994; 330: 592-596
        • Cosman B.
        • Feliciano W.C.
        • Wolff M.
        Pentazocine ulcers.
        Plast Reconstructive Surg. 1977; 59: 255-259
        • Executive Office of the President, Office of National Drug Control Policy (2004)
        Pulse Check. ONDCP, Washington, D.C2004
        • Faich G.A.
        Adverse-drug reaction monitoring.
        N Engl J Med. 1986; 314: 1589-1592
        • Foley K.
        The treatment of cancer pain.
        N Engl J Med. 1985; 313: 84-95
        • Fontanarosa P.B.
        • Drummond R.
        • DeAngelis C.D.
        Postmarketing surveillance.
        JAMA. 2004; 292: 2647-2650
        • Gossop M.
        • Griffiths P.
        • Powis B.
        • Strang J.
        Br J Psych. 1994; 164: 660-664
      2. Government Accounting Office (GAO) Report to Congressional Requesters: Prescription Drugs: OxyContin abuse and diversion and efforts to address the problem, Washington, D.C.; GAO-04-0110, 2003

        • Inciardi J.A.
        • Chambers C.D.
        Patterns of pentazocine abuse and addiction.
        N Y State J Med. 1971; 71: 1727-1733
        • Inciardi J.A.
        • Goode J.L.
        OxyContin and prescription drug diversion.
        Consumer Research. 2003; : 22-25
        • Joranson D.E.
        • Ryan K.M.
        • Gilson A.M.
        • Dahl J.L.
        Trends in medical use and abuse of opioid analgesics.
        JAMA. 2000; 283: 1710-1714
        • Knisely J.S.
        • Campbell E.D.
        • Dawson K.S.
        • Schnoll S.H.
        Tramadol post-marketing surveillance in health care professionals.
        Drug Alcohol Depend. 2002; 68: 15-22
        • Marsch L.A.
        • Bickel W.K.
        • Badger G.J.
        • Rathmell J.P.
        • Swedberg M.D.B.
        • Jonzon B.
        • Norsten-Hoog C.
        Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.
        J Pharmacol Exp Ther. 2001; 299: 1056-1065
        • National Institute on Drug Abuse, Community Epidemiology Work Group
        Epidemiologic Trends in Drug Abuse Advance Report. National Institutes of Health, National Institute on Drug Abuse. DHHS, Bethesda, MD2002
        • Oldendorf W.H.
        Some relationships between addiction and drug delivery to the brain.
        NIDA Research Monograph. 1992; 120: 13-25
        • Passik S.D.
        Same as it ever was? Life after the OxyContin media frenzy.
        J Pain Symptom Manage. 2003; 25: 199-201
        • Perry S.
        • Heindrich G.
        Management of pain during debridement.
        Pain. 1982; 13: 267-280
        • Piazza-Hepp T.D.
        • Kennedy D.L.
        Reporting of adverse events to MEDWatch.
        Am J Health Syst Pharm. 1995; 2: 1436-1439
        • Portenoy R.K.
        Inadequate outcome of cancer pain treatment.
        in: Patt R.B. Problems in Cancer Pain Management. J.B. Lippincott, New York, NY1992: 119-128
        • Porter J.
        • Jick H.
        Addiction rare in patients treated with narcotics.
        N Engl J Med. 1980; 302: 123
        • Rischitelli D.G.
        • Karbowicz S.H.
        Safety and efficacy of controlled release oxycodone.
        Pharmacotherapy. 2002; 22: 898-904
        • Roset P.N.
        • Farre M.
        • De La Torre R.
        • Mas M.
        • Menoyo E.
        • Hernandez C.
        • Cami J.
        Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males.
        Drug Alcohol Depend. 2001; 64: 285-298
        • Senay E.C.
        Clinical experience with T’s & B’s.
        Drug Alcohol Depend. 1985; 14: 305-311
        • Strom B.L.
        Potential for conflict of interest in the evaluation of suspected adverse drug reactions.
        JAMA. 2004; 292: 2643-2646
        • Substance Abuse and Mental Health Services Administration
        Results from the 2002 National Survey on Drug Use and Health. Office of Applied Studies, Rockville, MD2003 (NHSDA Series: H22, DHSS Publication No. SMA 03-3836,)
        • Substance Abuse and Mental Health Services Administration
        Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1995-2002. Office of Applied Studies, Rockville, MD2003 (NHSDA Series: D-24, DHSS Publication No. SMA 03-3780,)
      3. 34. U.S. Dept. of Health and Human Services, Food and Drug Administration May 1999. (Henney Report): Managing the risks from medical product use: creating a risk management framework. Available at: . Accessed April 5, 2005.

      4. 35. U.S. Dept. of Justice Drug Enforcement Administration Diversion Control Program: August 11, 2004. Prescription Pain Medication: Frequently Asked Questions and Answers for Health Care Professionals and Law Enforcement Personnel. Available at: Accessed April 5, 2005.

        • Ward S.E.
        • Goldberg N.
        • Miller-McCauley V.
        Patient barriers to management of cancer pain.
        Pain. 1993; 52: 319-324
        • Woody G.E.
        • Senay E.C.
        • Geller A.
        • Adams E.H.
        • Inciardi J.A.
        • Schnoll S.
        • Muñoz A.
        • Cicero T.J.
        An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride).
        Drug Alcohol Depend. 2003; 72: 163-168
        • Zacny J.
        • Bigelow G.
        • Compton P.
        • Foley K.
        • Iguchi M.
        • Sannerud C.
        College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse.
        Drug Alcohol Depend. 2003; 69: 215-232